Theranostics · 2023 · 27 citations · 31 references
MedicineOncologyPharmacologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmuno-oncology BiomarkersImmunotherapy For Solid TumorsTherapy Response AssessmentPd-l1 BlockadeProgrammed Cell Death Ligand 1 InhibitionProgrammed Death-1 BlockadeProgrammed Death-1 InhibitionProgrammed Death-ligand 1 BiomarkerProgrammed Death-ligand 1 InhibitionProgrammed Death-ligand 1 InhibitorsTreatment Efficacy Monitoring
Zr]Zr-DFO-KN035 can be used for the diagnosis and therapy monitoring of PD-L1-positive tumors and provide noninvasive and comprehensive observations for tumor diagnostic imaging, prognosis prediction, and efficacy evaluation.
31
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text
Medicine, Oncology, Pharmacotherapy +17